Recurrent, early-onset, major depressive disorder (RE-MDD) is a strongly familial condition whose malignant effects have a significant negative impact on the health and longevity of patients and their family members. Sixteen of the 19 candidate susceptibility loci identified by a recent genome survey revealed allelic associations with RE-MDD in men or women, but not in both sexes. The association of D2S2944 alleles and genotypes with RE-MDD and related disorders was evaluated using a case-control study design employing 100 adults with RE-MDD and 100 adult controls who had no personal or family history of mental disorders. The results of the case-control study were subsequently evaluated in a sample of 81 families ascertained through probands with RE-MDD using the transmission/disequilibrium test. The frequency of the D2S2944 124-bp allele among women with RE-MDD was approximately three times that for female controls (P = 0.0003). Women who carried the D2S2944 124-bp allele revealed a significantly elevated risk of developing RE-MDD, as indicated by an odds ratio of 4.5 compared to female controls (PϽ0.001). In contrast, men with RE-MDD did not have an increased frequency of this allele compared to male controls, and men who were carriers did not exhibit an increased risk of developing RE-MDD or related disorders. Our findings also suggest that the D2S2944 124-bp allele increases the risk of alcohol and other substance use disorders among women with RE-MDD. The transmission/disequilibrium test provided confirmatory evidence of these sex-specific findings within families. The results of this study confirm the existence of sex-specific susceptibility loci for RE-MDD, and suggest that there may be important differences in the molecular pathophysiology of RE-MDD in men and women. Alternatively, our findings may reflect the existence of sex-specific differences in the molecular mechanisms that determine resilience to endogenous or environmental depressogenic stimuli. The identification and characterization of the D2S2944 susceptibility locus for RE-MDD and related substance use disorders is likely to provide important new insights into the clinical biology, treatment, and prevention of these disorders.
Introduction
Unipolar Major Depressive Disorder (MDD) is characterized by 2 or more weeks of depressed mood or impaired enjoyment, with symptoms such as disturbed sleep and appetite, psychomotor changes, reduced concentration, excessive guilt, and suicidal thoughts or actions. 1 Most epidemiologic and family studies indicate that the lifetime prevalence of MDD is between 5% and 10%, with women twice as likely to be affected as men. [2] [3] [4] Suicide, a tragic consequence of MDD, has been reported to occur in 10-15% of patients who were previously hospitalized for depression, 5 a rate of death that is three orders of magnitude greater than that reported for the American population as a whole. 6 In addition to suicide, an even greater absolute increase in age-specific mortality from natural causes has been reported for individuals who suffer from MDD and their family members. 7 The significance of these public health problems has been highlighted by two recent reports from the Surgeon General. 6, 8 In a study conducted by the World Health Organization, MDD ranked second only to ischemic heart disease as a source of disability worldwide. 9 Twin studies have demonstrated that genetic factors typically account for 40-70% of the risk for developing MDD, [10] [11] [12] [13] [14] and adoption studies have confirmed the important role played by genetic risk factors in the development of MDD. [15] [16] [17] Consistent with these results, a large number of family studies have demon-strated an increased risk of MDD among relatives of MDD probands, with about a two-fold increased risk to first-degree relatives. [18] [19] [20] [21] [22] [23] [24] Early age at onset of the first major depressive episode 21, [24] [25] [26] [27] [28] as well as recurrence 21, [29] [30] [31] are independent factors that increase the morbid risk of MDD among family members. In a recent study of 81 families ascertained through adult probands with recurrent (Ն two episodes), early-onset (onset Յ 25 years) MDD (RE-MDD), 7 over one third of first-degree relatives and nearly one fifth of extended relatives suffered from MDD, prevalence rates that were 7.7 and 3.8 times greater than the corresponding population rates reported by the Epidemiologic Catchment Area Study. 3 The results of a genetic segregation analysis of this sample suggest that a major locus contributes to the expression of recurrent MDD and possibly other major mood disorders within families identified by probands with RE-MDD. 32 We recently reported the results of a systematic survey of the human genome, conducted at an average resolution of 10 cM, for the identification of simple sequence tandem repeat polymorphisms (SSTRPs) that target susceptibility genes for RE-MDD by virtue of linkage disequilibrium. 33 The efficiency of this association study was enhanced by genotyping pools of DNA from 100 adults with RE-MDD and 100 adult controls who had no personal or family history of mental disorders. This case-control strategy for identifying genetic determinants that contribute to the expression of complex, non-Mendelian human disorders, which we have also previously employed to identify susceptibility loci for Alzheimer's disease, [34] [35] [36] [37] [38] [39] [40] is receiving growing support in the human genetics community. 41 In our previous investigation, allelic associations with RE-MDD were observed for 19 of the 387 SSTRPs employed in the analysis. Sixteen of the 19 candidate susceptibility loci revealed significant allelic associations with RE-MDD in men (n = 7) or women (n = 9), but not both sexes. These findings suggest that sexspecificity of susceptibility loci for RE-MDD may be commonplace.
This report focuses on a candidate susceptibility locus for RE-MDD that was identified in our genome survey by D2S2944 (2q35), which revealed evidence of linkage disequilibrium with RE-MDD in women but not men. We describe the association of a specific D2S2944 allele (124 bp) with RE-MDD among women, estimate the increased relative risk of developing RE-MDD in women who carry this allele, and assess the effect of this allele on the development of comorbid mental disorders that frequently accompany RE-MDD. The results of the case-control study design were supported by evidence derived from a within-family analysis of the D2S2944 124-bp allele in 81 families previously identified through individuals with RE-MDD.
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Subjects and methods
Recruitment of subjects and families
One hundred (50 M/50 F) adults (18 years or older) with recurrent (two or more episodes), early-onset (first Molecular Psychiatry episode occurring at or before age 25), non-psychotic, unipolar, major depressive disorder (RE-MDD) were recruited and characterized, along with an equal number of healthy adults who had no personal or family history of mental disorders, for inclusion in a study to identify susceptibility genes for major depression and related disorders. 33 Subjects with RE-MDD had a mean age of 17.5 ± SD 4.2 yrs at the onset of their first depressive episode and had experienced a mean of 4.1 ± SD 2.4 episodes at the time of recruitment. Subjects in the unaffected comparison group were matched to the RE-MDD cases for age (as close as possible but at least as old), sex, race, and ethnicity. The age-matching strategy ensured that controls were similar in age but had lived at least as far into the age of risk for MDD as the RE-MDD cases to which they were matched. The mean ages of the RE-MDD and control groups were 32.8 ± SD 9.4 yrs and 37.6 ± SD 10.5 yrs, respectively. The ethnicity of each subject was determined in eighths by assigning a maximum of two ethnicities to each of his/her maternal and paternal grandparents from a standardized list of ethnic groups. To facilitate matching, ethnicities were condensed into five groupings: British, German, Latin, Slavic, and Other ( Table 1) . Matching of RE-MDD cases and controls for age and ethnicity was performed within gender so that casecontrol comparisons of allele frequencies could be made separately for men and women.
Eighty-one families were ascertained through adult probands with RE-MDD and included 407 first-degree relatives and 835 extended relatives, as previously described. 7 Selection criteria for families also included two living parents and at least one sibling who were willing to participate. Families were ascertained without consideration of the psychiatric diagnoses of any family member other than the proband.
This research project and associated recruitment materials were approved by the Institutional Review Board of the University of Pittsburgh. All subjects provided written informed consent prior to participation.
Clinical characterization of subjects and families
Diagnoses of subjects with RE-MDD included in the case-control analysis were formulated from structured personal interviews employing the Schedule for the Affective Disorders and Schizophrenia-Lifetime Ver- sion (SADS-L) 42 and available medical records. Controls had no lifetime histories of mental disorders, as determined by personal interviews employing the Structured Clinical Interview for DSM-III-R Axis I Disorders, Non-Patient Version (SCID-I-NP) 43 and the Structured Clinical Interview for DSM-III-R Axis II Personality Disorders (SCID-II), 44 and no family history of mental disorders among first-degree relatives. To assess the latter selection criterion, all living first-degree relatives underwent the same structured personal interviews as the controls. The psychiatric histories of deceased first-degree relatives were evaluated by structured family history assessments conducted with best informants. 45, 46 Psychiatric diagnoses for probands with RE-MDD and their family members who provided blood samples were formulated from structured personal interviews, including the SADS-L or the Kiddie-SADSEpidemiologic Version, 47 structured family history assessments, and available medical records. The remaining family members who participated and those who were deceased were evaluated through the family history method augmented by available medical records. The inter-rater reliability of the psychiatric diagnoses established from structured personal interviews, as well as the sensitivity and specificity of the family history method to accurately detect the presence or absence of mood disorders in these groups, have been established. 7, 33 All clinical assessments were performed by experienced mental health clinicians with regular supervision by an ABPN-certified faculty psychiatrist. Best estimate diagnoses were made using a consensus conference approach according to Research Diagnostic Criteria 48, 49 and the DSM-IV criteria. 1 
Laboratory procedures
Venous blood samples were obtained by antecubital phlebotomy by qualified clinical staff who coded the samples prior to transport to the laboratory. Lymphocytes were isolated under sterile conditions by centrifugation on an Histopaque-1077 step gradient according to the manufacturer's instructions (Sigma Chemical, St Louis, MO, USA), and lymphoblast cell lines were established by exposure of lymphocytes to Epstein-Barr virus. Genomic DNA was isolated from whole blood or blood cells at room temperature using minor modifications of standard methods as previously described. 33, 50 Genotyping of the tetranucleotide repeat polymorphism D2S2944 was performed using oligonucleotide primers provided in the CHLC Human Screening Set/Weber Version 9 (Research Genetics, Huntsville, AL, USA). One primer was 5Ј end-labeled with 32 P in a 10.5 l reaction mixture containing 50 pmol of primer, 12.5 Ci (␥-32 P) ATP (6000 Ci mmol
; NEN, Boston, MA, USA), and 7.5 U of T 4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA), in 1× polynucleotide kinase buffer (including 10 mM MgCl 2 ) provided by the manufacturer. Following incubation for 1 h at 37°C, each sample was diluted with 39.5 l of distilled water to a final primer concentration of 1 pmol l −1 . Amplification was carried out in a 12.5 l reaction mixture that included 20 ng of DNA, 1 pmol of endlabeled primer, 5 pmol of corresponding unlabeled primer, 200 M of each dNTP, 1.5 mM MgCl 2 , and 0.50 U of AmpliTaq DNA polymerase (Perkin-Elmer, Foster City, CA, USA) in 1× Taq polymerase buffer. Following denaturation for 5 min at 94°C, amplification was achieved by 30 cycles of denaturation for 0.5 min at 94°C, 0.5 min of annealing at 58°C, and 0.5 min of extension at 72°C, followed by a final extension step of 7 min at 72°C.
The resulting PCR products were resolved by electrophoresis under denaturing conditions and visualized by autoradiography. Fragment sizes were determined by comparison to individuals of known genotypes from the CEPH panel, 1331-01 and 1331-02 (Coriell Institute, Camden, NJ, USA). Genotypes of individual subjects were independently read from autoradiograms by two experienced research associates. The independent readings were compared for consistency before genotypes were entered into the laboratory database. Inconsistencies occurred at a rate of Ͻ1%. In cases where the experimental results were ambiguous or agreement could not be reached, the genotyping procedure was repeated.
Statistical analysis
Continuous variables were compared using the t statistic. Categorical variables were compared using the 2 statistic or Fisher's exact test, as appropriate. Statistical analysis of sociodemographic and clinical variables was performed using SPSS Version 10 (SPSS, Chicago, IL, USA). Frequencies of multiple alleles or genotypes of D2S2944 were compared between groups using the software packages CLUMP 51 and MedCalc (MedCalc Software, Mariakerke, Belgium). Within-family assessments of linkage and linkage disequilibrium were made using the transmission/disequilibrium test. 52 Two-tailed tests of significance were used in all cases.
Results
Our initial genome survey 33 was conducted by typing the DNA pools constructed from the RE-MDD and unaffected control groups for 386 of the 387 SSTRPs (one SSTRP did not produce interpretable results) represented in the CHLC Human Screening Set/Weber Version 9 (Research Genetics). Both groups included 50 men and 50 women so that susceptibility loci with sex-specific effects on the development of RE-MDD could be detected. Allelic distributions were compared between the case and control groups with 2 statistics (2 × n) whose statistical significance were determined by Monte Carlo simulations. Allelic associations with RE-MDD were observed for 19 SSTRPs. Sixteen of the 19 candidate susceptibility loci revealed significant allelic associations with RE-MDD in men (n = 7) or women (n = 9), but not both sexes. Significant differences in the distributions of D2S2944 alleles between cases and controls were detected for the combined sex groups ( 2 = 23.15, P = 0.001) and women ( 2 = 18.21, P = 0.003), but not for men ( 2 = 11.86, P = 0.09). Comparisons of individual D2S2944 allele frequencies (2 × 2) between women with RE-MDD and female controls are presented in Table 2 . The frequency of the D2S2944 124-bp allele among women with RE-MDD, 0.32 ± SE 0.05, was approximately three times that for female controls, 0.11 ± SE 0.03. Only the frequency of this allele differed significantly between these groups after a Bonferroni correction for multiple comparisons was made (P = 0.0003 × 7 = 0.002).
Only five of the 200 individuals in the study population were homozygous for the D2S2944 124-bp allele. The observation that four of these five homozygotes were women with RE-MDD (one was a male control) suggests that the D2S2944 124-bp allele may exert a dosage effect on the risk of developing RE-MDD among women, although the small number of homozygotes precluded an adequate analysis of allele dose on the expression of RE-MDD and related disorders. In light of the rarity of homozygotes, subjects were classified as carriers, whose genotypes included one or two D2S2944 124-bp alleles, or as noncarriers who lacked this allele. As shown in Table 3 , women who carried the D2S2944 124-bp allele manifested a significantly elevated risk of developing RE-MDD, as indicated by an odds ratio of 4.5 (95% confidence interval: 1.9-10.8, P Ͻ 0.001). In contrast, men who carried this allele did not exhibit an increased risk of developing RE-MDD, as reflected by an odds ratio that did not differ significantly from 1.0. The results for the combined-sex groups were intermediate between these values, with an odds ratio of 2.7 (95% confidence interval: 1.5-5.0, P = 0.001).
Phenotypic comparisons of individuals with RE-MDD who carried or lacked the D2S2944 124-bp allele are presented in Tables 4 and 5 . As shown in Table 4 , the mean age at study, mean age at first MDE, mean Both RE-MDD and control groups included 100 D2S2944 alleles, so numbers of alleles were identical to allele frequencies. All 2 statistics (2 × 2) had one degree of freedom. Only the 124-bp allele frequencies remained significantly different after Bonferroni corrections for multiple comparisons were made (P = 0.0003 × 7 = 0.002). lifetime number of MDEs, and prevalence of any comorbid mental disorder were similar for women with RE-MDD who carried or lacked the D2S2944 124-bp allele. Of the comorbid disorders, Alcohol and Other Substance Use Disorders were significantly more common among women with RE-MDD who carried the D2S2944 124-bp allele, than among non-carriers (P = 0.01). In fact, 10 of the 11 women with RE-MDD who also suffered from Alcohol or Other Substance Use Disorders carried the risk allele. Although these disorders commonly affect men more than women, women with RE-MDD in our study who carried the risk allele manifested Alcohol and Other Substance Use Disorders at a rate (35.7%) that was comparable to the men with RE-MDD (38.0%, Table 5 ). None of the other comorbid mental disorders differed significantly in prevalence between women who carried or lacked the D2S2944 124-bp allele, although this analysis was limited by sample size. None of the clinical features assessed, or comorbid disorders diagnosed by the SADS-L, differed significantly between men with RE-MDD who carried or lacked the D2S2944 124-bp allele ( Table 5 ). The last results provided no evidence of a clinical phenotype influenced by this allele in men. However, a trend toward decreased prevalence of Anxiety Disorders was observed for D2S2944 124-bp carriers of both sexes (P = 0.07). The exploration of this trend within individual Anxiety Disorders was limited by sample size.
Molecular Psychiatry
The evidence for linkage disequilibrium (association) of the D2S2944 124-bp allele and RE-MDD from our case-control study design was further evaluated by the transmission/disequilibrium test (TDT) in a collection of 81 families identified through probands with RE-MDD. 7 The TDT is based on the unequal probability of transmission of two different marker alleles (or groups of alleles) from parents to affected offspring, when the marker locus and the hypothetical disease locus are linked and in linkage disequilibrium. 52 Separate analyses were formed using parents and: (1) all informative RE-MDD offspring in a sibship; or (2) only one informative RE-MDD offspring (trios). The first informative affected offspring recruited for the study was chosen for inclusion in the analysis of trios. Calculations of the TDT statistic based on only one affected offspring sacrifice statistical power, but they may provide a more conservative test of linkage and linkage disequilibrium by ensuring that the contributions of all informative nuclear families are weighted equally.
As shown in Table 6 , the TDT provided evidence of linkage and linkage disequilibrium of the D2S2944 124-bp allele with RE-MDD among women in this collection of families ( 2 = 5.23, P = 0.02). The results remained statistically significant even when only one affected daughter per nuclear family was analyzed ( 2 = 4.26, P = 0.04). Also consistent with the results of the case-control study, there was no evidence for linkage or linkage disequilibrium of the D2S2944 124-bp allele with RE-MDD among men. The number of informative nuclear families that included sons with RE-MDD was modest, reflecting the excess of women among family members with RE-MDD. However, the lack of statistical significance of the TDT for men did not result merely from the lack of statistical power to detect an excess of D2S2944 124-bp alleles transmitted to affected sons because parents transmitted fewer 124-bp alleles than other D2S2944 alleles to their sons with RE-MDD.
Discussion
Results derived from both case-control and withinfamily studies indicate that D2S2944 identifies a locus that influences the susceptibility of women to developing RE-MDD, a severe and strongly familial form of unipolar MDD. It seems most likely that the observed association of the D2S2944 124-bp allele with RE-MDD in women resulted from linkage disequilibrium with a susceptibility gene in close proximity to the marker locus. While SSTRPs are rarely found within protein coding regions, we cannot exclude the possibility that the D2S2944 124-bp allele directly affected the susceptibility of RE-MDD among women by altering regulatory regions that influence mRNA transcription, processing, turnover, or translation. Examination of this region of chromosome 2 in the Human Genome Database did not reveal any genes of known function within 0.5 Mb flanking D2S2944. 53 Our results imply that there may be important differences in the molecular pathophysiology of RE-MDD in men and women. Several lines of phenomenological and biological evidence are consistent with this hypothesis, 33 although most of the data are derived from studies of unipolar MDD more generally rather than the RE-MDD subtype. Our findings may also reflect the existence of sex-specific differences in the molecular mechanisms that determine resilience to endogenous or environmental depressogenic stimuli, rather than different disorders among men and women who develop RE-MDD.
A potential limitation of linkage disequilibrium (association) mapping strategies that employ casecontrol study designs arises from the potential of detecting false positive findings from the inclusion of differing proportions of ethnic populations in the case and control groups. 41 In such cases, differences in marker allele frequencies may emerge at loci that differentiate the ethnic groups, even if they are unrelated to the phenotype of interest (stratification artifact). We addressed this potential limitation by restricting the study population to Caucasians and matching the cases and controls as closely as possible for ethnicity. Moreover, it seems unlikely that false positive results produced by this mechanism would be sex-specific, as Molecular Psychiatry observed for D2S2944 and 15 of 18 additional candidate susceptibility loci detected by our genome survey. This limitation was also addressed through the use of a within-family method that does not suffer from this potential confound. Results from the TDT provided confirmatory evidence of linkage and linkage disequilibrium of the D2S2944 124-bp allele with RE-MDD in daughters but not sons, findings that exclude stratification artifact as the explanation.
The susceptibility to developing most major psychiatric disorders is determined in part by contributions from risk alleles at multiple genetic loci. Emerging evidence suggests that some of these alleles are shared among more than one psychiatric disorder. 39, 54 At least some of the psychiatric 'comorbidity' that accompanies RE-MDD and unipolar MDD more generally may result from the range of behavioral phenotypes affected by the susceptibility alleles that contribute to the development of severe mood disorders. Recent evidence also suggests that the pleiotropic effects of susceptibility alleles for RE-MDD 7 and panic disorders 55 may increase the likelihood of developing disorders of organ systems other than the central nervous system that have important independent effects on mortality.
Our findings suggest that the D2S2944 124-bp allele may also increase the risk of Alcohol and Other Substance Use Disorders among women in addition to RE-MDD, at least among women with the latter disorder. The abuse of alcohol and other substances by some patients may result from efforts to alleviate the symptoms of depression ('self medication'). However, this mechanism could not account for the increased comorbidity of these disorders among women with RE-MDD who carried the D2S2944 risk allele, because the comparison group of women noncarriers also suffered from RE-MDD. Moreover, women with RE-MDD who carried or lacked the D2S2944 124-bp allele appeared to have mood disorders of similar severity as reflected by the age at onset, lifetime number of MDEs, and overall prevalence of comorbid mental disorders. It is noteworthy that D2S2944 resides in close proximity 53 to a locus that revealed suggestive evidence of linkage to 'comorbid alcoholism and depression' in a collection of families identified through probands with alcohol dependence/alcoholism. 56 Our future efforts will include evaluations of the range of phenotypes affected by the D2S2944 124-bp allele using both case-control and within-family study designs.
The significance of identifying susceptibility loci that influence the development (either increased risk or protection from) RE-MDD is manifold. The tools of reverse genetics will eventually lead to the identification and characterization of molecular and cellular pathways that participate in the pathogenesis of RE-MDD, and the cell populations and neural circuits in which they act. Such efforts will provide insights into the pathophysiology of this malignant condition, new opportunities for drug development and disease prevention, and fundamental information about the human biology of mood and its regulation. Meanwhile, the introduction of genotyping for anonymous loci (eg SSTRPs) that serve as proxies for as yet undetermined susceptibility genes into epidemiologic, biologic, clinical, and treatment studies, may reveal genetic subtypes of RE-MDD that manifest greater pathogenetic homogeneity than the syndrome as a whole. This approach to reducing the variance in disease pathogenesis may be equally important in the evaluation of experimental drugs or other interventions that may treat or prevent disabling episodes of major depression and other sequelae. This strategy may also contribute to the improved effectiveness of currently available treatments by enabling practitioners to use genotypes to better match individual patients to those treatments to which they will optimally respond while minimizing toxicity.
